10:59 AM EDT, 03/15/2024 (MT Newswires) -- Cybin ( CYBN ) said Friday it has initiated a phase 2 proof-of-concept study to evaluate the safety and efficacy of CYB004 for the treatment of generalized anxiety disorder.

The study will recruit about 36 participants, with topline safety and efficacy data expected in Q4, the company said.

The stock was up more than 4% in recent trading.

Price: 0.45, Change: +0.02, Percent Change: +4.87